• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Preventive Medicine: An International Journal Devoted to Practice and Theory >Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis
【24h】

Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis

机译：用于预防19岁及19岁及以上的成年人的百日咳（TDAP）疫苗（TDAP）疫苗：成本效益分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Currently, the Advisory Committee on Immunization Practices recommends one-time tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination for all adults 19 years and older. This study is designed to evaluate the cost-effectiveness of Tdap vaccination for Tdap-eligible adults aged 19 through 85 in the United States. A cost-effectiveness model was developed to compute costs and health outcomes associated with pertussis among 100,000 Tdap-eligible persons of each age cohort. From the societal perspective, the cost per quality-adjusted life-year (QALY) saved was evaluated under the vaccination scenarios. Sensitivity analyses were also conducted to evaluate the impacts of changes in key variables. All costs were adjusted to 2018 US$ with an annual discount rate of 3% applied to costs and outcomes. The incremental cost-effectiveness ratios (ICERs) for vaccinating US adults aged 19 to 85 with Tdap ranged from $248,000/QALY to $900,000/QALY. The lowest cost per QALY was found to be $248,000 for the age 65 cohort, followed by $332,000 for the cohort of age 19, and followed by $477,000 for the age 50 cohort. Sensitivity analysis showed the most dramatic changes in ICER occurred when changing the underreporting factor, vaccine effectiveness and vaccination costs. While Tdap vaccination may not be as cost effective as predicted earlier, it remains the best available preventive measure against pertussis. Further investigation of the true burden of pertussis disease among adults and the effectiveness of Tdap vaccination in this population is needed to better estimate the impact of Tdap vaccination.
机译：目前，免疫惯例咨询委员会建议为19岁及以上所有成年人减少的破伤风毒素，减少白喉类毒素，减少白喉类毒素和患者疫苗（TDAP）疫苗接种。本研究旨在评估19至85岁至85岁的TDAP疫苗接种TDAP疫苗接种的成本效益。开发了一种成本效益模型，以计算与每年召开的10万个TDAP符合条件的人中百日咳相关的成本和健康结果。从社会的角度来看，在疫苗接种场景下评估了保存的每个质量调整的生命年份（QALY）的成本。还进行了敏感性分析，以评估关键变量变化的影响。所有费用调整为2018美元，每年贴现3％的贴现率适用于成本和成果。与TDAP接种19至85岁至85岁的美国成年人的增量成本效益比率（ICER）范围从248,000美元/ QALY到900,000美元/ QALY。 65岁的队列，每QALY的最低成本为248,000美元，其次为19岁的队列332,000美元，其次为50岁的队列477,000美元。敏感性分析显示，在改变潜断因子，疫苗效果和疫苗接种成本时发生了ICER中最戏剧性的变化。虽然TDAP疫苗接种可能不如之前预测的成本效益，但它仍然是对Pertussis的最佳可用措施。进一步调查成人中百日咳疾病的真正负担以及该群体中TDAP疫苗接种的有效性，以更好地估计TDAP疫苗接种的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号